Companies / United States
BMS Considers Baby Food Divestment?
March 2008 | Industry NewsUS-based drugmaker Bristol-Myers Squibb (BMS) is reported to be feeling out potential buyers for its baby formula business, Mead Johnson. The unit is valued at between US$7bn-US$9bn and if it is successfully divested it will be the latest instance of the de-coupling trend seen in the global pharmaceutical market.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
